account(BUSINESS WIRE) -- Allergan, Inc. /quotes/comstock/13*!agn/quotes/nls/agn AGN +2.56% and Molecular Partners AG today announced that they have entered into a license agreement for MP0112, a phase II proprietary therapeutic DARPin(R) protein targeting...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Allergan and Molecular Partners Enter into an Exclusive License Agreement For MP0112 For the Treatment of Retinal Diseases
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account